NCT02825914 (CAGLUCIM) is a NA clinical trial of Casein glycomacropeptide (CGMP) in Colitis, Ulcerative, sponsored by University of Aarhus.

Who is sponsoring NCT02825914?

NCT02825914 is sponsored by University of Aarhus.

What drugs are being tested in NCT02825914?

Interventions in NCT02825914: Casein glycomacropeptide (CGMP), Placebo.

What condition does NCT02825914 study?

NCT02825914 studies Colitis, Ulcerative, Inflammatory Bowel Diseases.

Is NCT02825914 still recruiting?

NCT02825914 is currently completed. Last updated 7 April 2020.

Last reviewed 2020-04-07 · How we verify

NCT02825914: CAGLUCIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)

Completed NA Last updated 7 April 2020

What this trial tests

NA trial testing Casein glycomacropeptide (CGMP) in Colitis, Ulcerative in 80 participants. Completed in 1 October 2019.

Timeline

1 September 2016

Primary endpoint
1 July 2019

1 October 2019

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	1 September 2016
Primary completion	1 July 2019
Estimated completion	1 October 2019
Sites	1 location across Denmark

Drugs / interventions tested

Casein glycomacropeptide (CGMP)
Placebo

Conditions studied

Colitis, Ulcerative — all drugs for Colitis, Ulcerative →
Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Colitis, Ulcerative or Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. In a pilot study the investigators found, that orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis. The investigators wish to evaluate the effects in a larger group of patients with active ulcerative colitis by studying the clinical effects and assessing the anti-inflammatory and microbiome modulating properties.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.
Oka A, Sartor RB. · · 2020 · cited 126× · PMID 32006212 · DOI 10.1007/s10620-020-06090-z

Verify or expand the search:

Other trials of Casein glycomacropeptide (CGMP)

Trials testing the same drug.

NCT05482464 — Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irrita · NA · completed

Other recruiting trials for Colitis, Ulcerative

Currently open trials in the same condition.

NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02825914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 7 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02825914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing